CFO, that lay for growth questions. be follow results, and On available with both today's discussion second financial and the everyone to overview our our answer then Yes, morning. accomplishments a many us will Fred call this of my during thank to of an you, thanks And initiatives. Leffler, groundwork will helps us Tirth. I'll on the value-driving strategy provide our joining quarter
R&D tremendous made areas, update, sales we our expanding the our optimizing with progress clinical have force, including advancing critical across Starting business and and initiatives. three structure, cost
commend announced as year-over-year. increase we I sales, revenue for would $X.X like to a Regarding of the XX% the quarter million, team net
While share Ameluz during lamps BF-RhodoLED more proud XX at physician majority are revenue, the of the ago. vast we the also that makes number to up quarter, twice placed a year than the offices
patients. a growing provide first-term installations adding in lamps number already field lamp with more both dermatologists to installations, More sites bought one XX The among XX already future lamps are lamp Clearly, to to in and and about of Ameluz-PDT treatment remaining of recognition specifically, offices of had a their reflects second the Ameluz-PDT. The XX the familiar approximately and now place growth, proxy are and keratosis. actinic for BF-RhodoLED-PDT. placements an with delighted for the patient-friendly increasing are up start Ameluz-PDT as we set effective lamp Ameluz
grown intend During the last focus, the reaching We of sales strategic in some have team. with have we reduced had support. we strategic growing our also our hirings, achieved share we To utilize shifts I'll force, workforce force. best growing parts quarter's to sales today's and, new the of call, we introduced reimbursement goal members. support for in and sales call, other the compensate how of to approach and business. the Subsequent our XX the new strategy On a our medical for
approach sales to regions potential. To more metropolitan our shown and a and more growth, surgical adopting we results leaner optimizing path of high great sales strategy. are a consistently maintain Certain have strategic for
the campaigns, potential. enhanced have sales and sales high our areas, both expanded in in channeling initiatives, demonstrated teams sales be more number will We representatives training revenue support includes This these terms existing down increase the of and metropolitan of road. territories capital human in and marketing resources, reimbursement affairs medical that a into potential for
the On territories, we data by This areas assets, our out and not stay lower invested if smarter redeployed stand. towards those recalibrate marketing have lower comparatively with resources return By regions cases, certain to shift better with profitability. and greater By in decided intentional to a market generating and for in have driven that on being agile build can optimizes been homing that teams our is demands. to our to we are growth we strategy new high-value we responsive and or revenues we sales have efforts, expand flip on side, being and and our sales opportunity. needed more able metals, achieve ensure
current in QX, made implement crucial driven to was centered reduction our necessity decision our to This less streamline was to to the During around phase difficult by force. the and reduce of we operations reduction decision a primarily costs. growth. The holds small
dialing simultaneously However, we areas, while step to in positioned Biofrontera we we adjustments, revenue-generating took two and agile heightened driving higher as bolstering more in a be took focus By revenues. with in certain others, back these leaner positions. forward a have such steps on
R&D portfolio expansion now at Ameluz. for studies key active innovation value Biofrontera. of A taking Let driver label and turn the me to place is our
Ameluz-PDT we yesterday, announced for the SBCC. or superficial phase in of Basal combination clinical the patients Just is Carcinoma, X enrollment complete study that now XXX treatment with all of in Cell evaluating BF-RhodoLED
into treating next currently will is with these as for BF-RhodoLED-PDT offer all field-directed in neoplastic include treatment U.S. label to Ameluz treatment pre-malignancies lesions, to invasive, Adding cases Approximately We need results SBCC the damage two-thirds as to look approved in of medical underlying it larger our skin larger to X without a are sharing sun-induced goal skin radiation. one doctors, phase lesions keratosis. therapies in forward actinic in is as addition well the cost-efficient fields unmet logical BCC of and in treat to leading this the of It that significant effective, BCC, from sun-damaged SBCC cancer ionizing mid-XXXX. more individual to step Ameluz areas. for for non-melanoma less allow study the
label face the a is actinic demand Regarding AK therapy growing large within a scalp. Ameluz for effective there highly and keratosis, beyond expanding to treat and the
of phase and evaluating study We total stratified Ameluz in dosed on-going and use region. subjects enroll extremities, the neck, X currently an of aim the centers. XXX XX have to body by have We across XX a enrolling, patients trunk, PDT
Lastly, for three-tube safety after study analyzing potential of investigating final treatment. treatment. the tubes X patient completed are to from study, multi-center open-label currently phase results be has phase tolerability clinical the the the per three the FDA approval required the we Ameluz This study study, for our final safety and of
submission track be FDA for very Results as before soon, available year-end. remain will we on an
aware, therapy. PDT BF-RhodoLED RhodoLED XL, for lamps, are red you our and of by in most photodynamic only dermatology approved and solutions remarkable use FDA As lights the in are the
infrastructure PDT to and However, specialized for limited the clinics is fixed or dermatology facilities. mostly current
with and and a lamp. of The the is in the the form, low-cost Recognizing now lamps mind. flexibility two patient new engagement locations, the constraints posed portable the demand in to current new the of physician the contract treatment and growing manufacturer quality we announced to by in for patents of develop under prototype a the PDT PDT aims lamps both stationary accessible development deliver RhodoLED of designed more acquiry in have a June, nature and U.S. granted and the
to an physician's Its allowing lamp to clinicians with and storage at dermatologists portability to mobile will The compact and expand our areas. offices. underserved furthermore reach to for patient. space more be portable it remote be bring A designed for lightweight, the the allows more option constraints is dermatology to reaching enabling and clinics offices lamp lamp easy or and
at demonstrations at transported a or allows give offices. a in From portable, can our presented easily of perspective, sales team live lamp it back a physician car to Being the conferences. sales be be
embodies prioritize commitment care and that solutions to PDT Biofrontera’s expand innovative portable Our lamp access.
to during you I development the keeping forward process. look updated
a to protocol example a as final and care quarter, a novel followed of new related effective. second far less protocol friendly. we granted As to that expected the light, painful our with patent of but to to be the commitment spectrum patient is minutes red innovation, applications during is equally XX similar more patient PDT to light gel exposure With an incubation wavelength this illumination, between with were of by sunlight,
This granted Friendlier the to months, price will Xst, purchases patent protecting causing XXXX. for in protocols increase of and it on Ameluz by expires dermatologists is U.S. accelerate April last the the in their Office to by XX help Patent April Ameluz the some QX. fourth X% into
we Ameluz a solid were such We strong QX second have of raised ahead revenues, by actions, price still year. in of any half are revenues in not our XXXX, of the and and not the growth and indicating thus impacted XXXX XXXX
investment was million medical fares million quarter $XX.X due revenue-generating for million of second last by as as driven to million operating we quarter $X of and our increase more costs year. million XXXX, mentioned. compared with reimbursement, first approximately Salesforce year-to-date, cost roles, were $XX.X the $XX.X increased Total months compared for to six million the in and The $X.X XXXX, second severance along some of expenses the resources of Herman with with pivoted and $XX.X for expansion
was one-time than for was sales analysts. of the of last year, settlement million of first reflects in of higher of XXXX. And second $X.X approximately half litigation Cost which fees due and of about the the million, was revenue $X.X to quarter increase quarter legal the a from XX% higher
general million, and compared months with Cost expenses were administrative for of quarter, $XX.X revenue Selling, $X.X for million the XX%. six up the year. $X.X million last first approximately was
with this months For $XX.X expenses were year, compared first the in $XX.X months first million, six of SG&A six XXXX. the of million
of note the with our quarter And The $X.X basis. Salesforce, the I on per for driven the the functions, these prior or includes mentioned, a loss was XXXX $X.XX $X.XX by a of $XXX,XXX, that legal per this into year costs net I primarily post-split non-recurring of or quarter. was will million, increase second loss and for share, figures expansion share. net realigning are As compares revenue-generating also SG&A expenses. the
was which outstanding the value Net change six first was primarily of the of million, months XXXX for first months the compared XXXX, a the of income for with of result warrants. loss net $XX.X million a $X.X six in fair of
for driven months offset the million, SG&A income I non-cash year. period negative increased six items, representation non-GAAP XXXX. we loss or table revenues. $X.X a to issued the $X.X million in $XX.X refer financial to with was first by better for the for during Adjusted compared compared for of this business's last of was million partially net the we adjusted the of costs, multiple you million morning the quarter, release the to decrease GAAP to year refer reconciliation $X.X measures. news Adjusted EBITDA in same negative comprises earlier higher was by As The status. negative EBITDA EBITDA
as million of June our equivalents XXst cash to as XXth, of balance of and sheet, XXXX. $X.X December cash $XX.X Turning had compared million, of we with
operations, from orders XXXX on to spent in Aside increased XXXX. I chain lingering we would into early than Due XXXX, concerns like. some inventory inventory have more supply we in
anticipating not XXXX closely. manage any of are the our a first half to result, inventory will purchases for continue making and We capital very we working as
strong on previously our our XXXX on we advancing hit track, along to higher optimized we results, to financial guidance. expansion With goals. label Based force are the on produce affirming opportunities able track quarter's returns, an sales with announced are
months With far, PDP to revenue for and we within for and cash in on XXXX, indicators a half and expect growth the ahead based least the one expect flow positive at of compared so multiple with us, be years. approximately strongest XX% year positive
are financial recent analysts. now With our overview and that business performance, ready I to from Herman covering take our Operator? and questions of
